Breast Cancer Core Needle Biopsy Market Size | Companies
The global breast cancer core needle biopsy market size was estimated at around USD 822.03 million in 2023 and it is projected to hit around USD 1,331.37 million by 2033, growing at a CAGR of 4.94% from 2024 to 2033.
The breast cancer core needle biopsy market is witnessing significant growth driven by the increasing prevalence of breast cancer and the demand for minimally invasive diagnostic procedures. Core needle biopsy (CNB) is a preferred diagnostic tool for detecting breast cancer due to its accuracy, minimal invasiveness, and cost-effectiveness. This procedure involves extracting small samples of breast tissue using a hollow needle, which are then analyzed to diagnose the presence and type of cancer.
The growth of the breast cancer core needle biopsy market is primarily driven by an increasing incidence of breast cancer globally, which necessitates early and accurate diagnostic tools. Additionally, advancements in biopsy technology, including the development of more precise and minimally invasive core needles, have enhanced the effectiveness and safety of these procedures, making them more widely adopted. The rising awareness about the importance of early cancer detection, supported by governmental and non-governmental screening programs, is also contributing significantly to market expansion. Furthermore, the growing preference for minimally invasive procedures among patients and healthcare providers is accelerating the demand for core needle biopsy as an essential diagnostic method in breast cancer care.
Integration of Artificial Intelligence (AI): AI is increasingly being integrated into diagnostic processes, including core needle biopsies. AI-powered tools can assist in image analysis, helping radiologists and pathologists detect abnormalities with greater accuracy and efficiency.
Personalized Medicine: The move towards personalized medicine is influencing the Breast Cancer Core Needle Biopsy Market. As treatments become more tailored to individual patient profiles, precise diagnostic tools like core needle biopsies are essential for identifying specific cancer types and guiding treatment decisions.
Rising Demand in Emerging Markets: Emerging economies are experiencing an increase in breast cancer cases and improving healthcare infrastructure. This is leading to higher demand for advanced diagnostic tools, including core needle biopsies, as awareness and access to healthcare services expand.
Focus on Patient Comfort and Experience: There is a growing emphasis on improving patient comfort during core needle biopsies. Innovations such as smaller gauge needles and enhanced anesthetic techniques are being developed to reduce pain and anxiety associated with the procedure, thereby improving the overall patient experience.
Risk of False-Negative Results: One of the primary challenges in the Breast Cancer Core Needle Biopsy Market is the risk of false-negative results, where a biopsy may miss cancerous tissue. This can lead to delayed diagnosis and treatment, impacting patient outcomes and trust in the procedure.
High Procedure Costs: The cost of core needle biopsy procedures can be a significant barrier, particularly in developing regions. Limited access to advanced healthcare facilities and the high expense associated with the necessary imaging equipment can restrict the adoption of this diagnostic method.
Lack of Skilled Professionals: Performing a core needle biopsy requires a high level of expertise and precision. In many regions, there is a shortage of trained radiologists and pathologists, which can affect the accuracy of the procedure and limit its widespread adoption.
Patient Anxiety and Discomfort: Despite being minimally invasive, core needle biopsies can still cause significant anxiety and discomfort for patients. Concerns about pain and the potential need for multiple procedures can deter some individuals from opting for this diagnostic method.
In 2023, the ultrasound-based breast biopsy segment dominated the global market with a 42% share and is projected to grow at the fastest CAGR during the forecast period. This segment's leadership is driven by the increasing adoption of ultrasound-based biopsies, recognized for their superior benefits. Additionally, the surge in product launches and approvals is anticipated to further boost the segment's growth.
For example, in April 2021, Mammotome launched the HydroMARK breast biopsy site marker, enhancing long-term ultrasound visibility. Similarly, in August 2023, TransMed7, LLC introduced the SpeedBird, an advanced breast biopsy device that facilitates easier image-guided biopsies. These industry advancements are expected to propel segment growth.
The CT-based segment held the second-largest market share, attributed to technological advancements in CT breast biopsies and the growing accessibility of this technology. Moreover, increasing research and development activities are expected to positively influence segment growth. Innovations like FDG PET/CT and FES PET/CT have also enhanced the treatment and diagnostic landscape for metastatic breast cancer.
In 2023, the hospitals and diagnostic laboratories segment captured a significant 60% market share. The growing number of patient visits to hospitals, coupled with the increasing adoption of advanced instruments and equipment, is fostering a favorable environment for segment growth. This segment is also anticipated to register the fastest CAGR during the forecast period, driven by the rapid installation of biopsy instruments. For instance, in July 2021, five major U.S. hospitals installed GE Healthcare’s advanced biopsy solution, Serena Bright, a development expected to positively impact segment growth.
The academic and research institutes segment is projected to experience substantial growth over the forecast period. Increased investments in academic centers to support research activities are likely to drive segment expansion. For instance, in October 2023, the Bren Simon Comprehensive Cancer Center and Indiana University Melvin received $2.2 million in funding for metastatic breast cancer research.
North America accounted for the largest share of the global breast cancer core needle biopsy market in 2023, with approximately 46%. This strong market leadership is attributed to the region's advanced healthcare systems, robust research capabilities, and dedicated efforts to raise awareness about early breast cancer detection and management. Renowned medical institutions and diagnostic centers in the U.S. and Canada consistently emphasize the importance of regular screenings. For example, the Mayo Clinic, recognized as a Specialized Program of Research Excellence (SPORE) for breast cancer research by the National Cancer Institute, highlights the significance of these efforts. Such initiatives contribute to higher adoption rates, positioning North America as a market leader.
A key factor in North America's dominance in breast cancer core needle biopsies is the integration of artificial intelligence (AI) into diagnostic processes. AI-powered tools are widely used across the region to assist pathologists in accurately interpreting biopsy results, reducing subjectivity and potential errors. This technological innovation enhances diagnostic accuracy and underscores the region's commitment to pioneering healthcare solutions. Meanwhile, Asia Pacific is expected to grow at the fastest rate during the forecast period, driven by the rising prevalence of breast cancer and the increasing demand for novel diagnostic technologies.
By Technology
By End-use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Core Needle Biopsy Market
5.1. COVID-19 Landscape: Breast Cancer Core Needle Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Core Needle Biopsy Market, By Technology
8.1. Breast Cancer Core Needle Biopsy Market, by Technology, 2024-2033
8.1.1. MRI-Based Breast Biopsy
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Ultrasound-Based Breast Biopsy
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Mammography-Based (Stereotactic) Breast Biopsy
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. CT-Based Breast Biopsy
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Other Image Based Breast Biopsy
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Breast Cancer Core Needle Biopsy Market, By End-use
9.1. Breast Cancer Core Needle Biopsy Market, by End-use, 2024-2033
9.1.1. Hospitals & Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Pharmaceutical & Biotechnology companies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Academic & Research Institutes
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Breast Cancer Core Needle Biopsy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2021-2033)
10.1.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2021-2033)
10.2.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2021-2033)
10.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 11. Company Profiles
11.1. Intact Medical Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Ethicon Endo Surgery
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Galini SRL
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Leica Biosystems Nussloch GmbH
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Hologic Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Argon Medical Devices
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Encapsule Medical Devices LLC.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cook Medical Incorporated
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Becton & Dickinson Company
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. C.R. Bard, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers